Mater Misericordiae University Hospital, Dublin, Ireland.
University College Dublin, Dublin, Ireland.
J Antimicrob Chemother. 2019 Nov 1;74(Suppl 5):v39-v46. doi: 10.1093/jac/dkz455.
Hepatitis C is one of the main causes of chronic liver diseases worldwide. One of the major barriers to effecting EU- and WHO-mandated HCV elimination by 2030 is underdiagnosis. Community-based screening strategies have been identified as important components of HCV models of care. HepCheck Europe is a large-scale intensified screening initiative aimed at enhancing identification of HCV infection among vulnerable populations and linkage to care.
Research teams across four European countries were engaged in the study and rolled out screening to high-risk populations in community addiction, homeless and prison services. Screening was offered to 2822 individuals and included a self-administered questionnaire, HCV antibody and RNA testing, liver fibrosis assessment and referral to specialist services.
There was a 74% (n=2079) uptake of screening. The majority (85.8%, n=1783) were male. In total 44.6% (n=927) of the sample reported ever injecting drugs, 38.4% (n=799) reported ever being homeless and 27.9% (n=581) were prisoners. In total 397 (19%) active HCV infections were identified and 136 (7% of total sample and 34% of identified active infections) were new cases. Of those identified with active HCV infection, 80% were linked to care, which included liver fibrosis assessment and referral to specialist services.
HepCheck's screening and linkage to care is a clear strategy for reaching high-risk populations, including those at highest risk of transmission who are not accessing any type of care in the community. Elimination of HCV in the EU will only be achieved by such innovative, patient-centred approaches.
丙型肝炎是全球慢性肝病的主要病因之一。到 2030 年实现欧盟和世界卫生组织规定的丙型肝炎消除目标的主要障碍之一是漏诊。基于社区的筛查策略已被确定为丙型肝炎护理模式的重要组成部分。HepCheck Europe 是一项大规模强化筛查计划,旨在提高弱势人群中丙型肝炎感染的识别率,并将其与护理联系起来。
来自四个欧洲国家的研究团队参与了这项研究,并在社区成瘾、无家可归者和监狱服务部门向高危人群推出了筛查。共向 2822 人提供了筛查,包括自我管理问卷、丙型肝炎抗体和 RNA 检测、肝纤维化评估和转介至专科服务。
筛查的参与率为 74%(n=2079)。大多数(85.8%,n=1783)为男性。样本中共有 44.6%(n=927)报告曾注射过毒品,38.4%(n=799)报告曾无家可归,27.9%(n=581)曾入狱。共发现 397 例(19%)丙型肝炎活跃感染,136 例(占总样本的 7%和已识别活跃感染的 34%)为新发病例。在已确定的丙型肝炎活跃感染者中,有 80%与护理联系,包括肝纤维化评估和转介至专科服务。
HepCheck 的筛查和与护理的联系是一种明确的策略,可以接触到高危人群,包括那些在社区中无法获得任何类型护理的最高传播风险人群。只有通过这种创新的、以患者为中心的方法,才能在欧盟消除丙型肝炎。